Pulmonary inflammation can cause shallow breathing and the lungs to become brittle in patients who experience multiple blood transfusions, sepsis, lung surgery and acute lung trauma.
New Penn Study Shows Drinking Alcohol, Even Light-to-Moderate Amounts, Provides No Heart Health Benefit
Reducing the amount of alcoholic beverages consumed, even for light-to-moderate drinkers, may improve cardiovascular health, including a reduced risk of coronary heart disease, lower body mass index (BMI) and blood pressure, according to a new multi-center study published in The BMJ and co-led by the
It wasn’t until she was 18 years old that Jordi Rivera Prince, a rising junior at the University of Pennsylvania, learned in depth about evolution.
Penn Study Finds Living Kidney Donation Does Not Increase Risk of Death or Heart Disease for Older Adult Donors
Previous studies linking older age with kidney and heart disease have raised concerns about the safety of living kidney donation among older adults.
Baligh Yehia of the Perelman School of Medicine comments on studying hepatitis C treatment in the U.S.
A team of scientists and physicians at the University of Pennsylvania will lead a four-year effort worth as much as $22.5 million to develop next-generation technologies to restore memory function in people who suffer from memory loss due to disease or traumatic injury.
A University of Pennsylvania-developed personalized immunotherapy has been awarded the U.S. Food and Drug Administration’s Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia (ALL).
For the last century, the concept of crystals has been a mainstay of solid-state physics. Crystals are paragons of order; crystalline materials are defined by the repeating patterns their constituent atoms and molecules make.
John Wherry, PhD, an associate professor of Microbiology in the Perelman School of Medicine at the University of Pennsylvania, and colleagues from Massachusetts General Hospital (MGH) are co-directing a $12 million grant to study immune responses in people who have been effectively cured of hepatitis C viral infection with new, high-potency antiviral drugs.